Summary
Regeneron Pharmaceuticals, Inc. (REGN) announced the commencement of a Phase 2 clinical trial for its VEGF Trap drug candidate. This study, conducted in partnership with sanofi-aventis Group, will evaluate the efficacy and safety of VEGF Trap in patients with advanced or metastatic non-small cell lung adenocarcinoma that is resistant to platinum and erlotinib treatments. The trial is designed to assess the objective response rate, as well as safety and survival metrics, providing crucial data on the potential of VEGF Trap in a difficult-to-treat cancer population. The initiation of this Phase 2 trial represents a significant step forward in the development of VEGF Trap. The trial's design focuses on a specific patient group with unmet medical needs, and the results will be critical for determining the drug's further development path. Investors should closely monitor the progress and outcomes of this study, as it directly impacts the future commercial potential of one of Regeneron's key pipeline assets.
Key Highlights
- 1Regeneron and sanofi-aventis have initiated a Phase 2 clinical trial for VEGF Trap.
- 2The trial targets patients with platinum- and erlotinib-resistant non-small cell lung adenocarcinoma.
- 3The primary goal is to assess the objective response rate of VEGF Trap.
- 4Secondary endpoints include safety, duration of response, progression-free survival, and overall survival.
- 5The study is a multicenter, open-label, single-arm, two-stage trial.
- 6VEGF Trap is administered intravenously every two weeks at a dose of 4.0 mg/kg.
- 7Information regarding the trial (NCT00284141) is available on www.ClinicalTrials.gov.